Riskpilot← Back to searchSign inGet full accessSobrera Pharma AB
ABActiveOrg 5592026271Karl Gustavsgatan 12 BResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20191-4 employees
Revenue 2024
SEK 0
EBITDA margin
—
+1% vs 2023
Equity ratio
84.3%
Financial strength
Net profit 2024
SEK -5M
-11% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -4,7M | +1% |
| Net profit | SEK -5M | -11% |
| Total assets | SEK 59,6M | +5% |
| Equity | SEK 50,2M | -9% |
| Employees | — | — |
Legal name
Sobrera Pharma AB
Org number
5592026271
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
15 april 2019
Share capital
SEK 105 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva utveckling syftande till kommersiell exploatering av nya diagnostiska test och behandlingsmetoder inom medicin, bland annat psykiatri-området och därmed förenlig verksamhet.
Address
Karl Gustavsgatan 12 B
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 2 437 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — |
| EBITDA | −107 | −194 | −2 305 | −4 718 | −4 733 | −4 671 |
| Depreciation & amort. | −0 | −0 | −13 | −16 | −16 | −3 |
| EBIT | −107 | −194 | −2 318 | −4 734 | −4 749 | −4 674 |
| Net financials | — | — | — | 42 | 232 | −324 |
| Profit before tax | −107 | −194 | −2 318 | −4 692 | −4 518 | −4 997 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −107 | −194 | −2 318 | −4 692 | −4 518 | −4 997 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 658 | 32 773 | 31 079 | 53 442 | 56 541 | 59 587 |
| Equity | 433 | 32 436 | 30 118 | 49 501 | 55 230 | 50 232 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 8 332 |
| Short-term debt | 225 | 336 | 961 | 3 942 | 1 311 | 1 023 |
| Total debt | 225 | 336 | 961 | 3 942 | 1 311 | 9 355 |
EBITDA margin
-467100000.0%
This company
15.8%
Market median
-2956329214% vs market
20192024
Equity ratio
84.3%
This company
38.2%
Market median
+121% vs market
20192024
Return on equity
-9.9%
This company
18.4%
Market median
-154% vs market
20192024
Net profit margin
-499700000.0%
This company
8.1%
Market median
-6169135902% vs market
20192024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192024
Debt / equity
0.19×
This company
0.62×
Market median
+69% vs market
20192024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-04-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LA Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
AS | Audit | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2025 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sobrera Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Ann-Charlotte Rosendahl | Chief Executive Officer | 0 companies |
| Anders Stig Arthur Sandquist | Audit | 0 companies |
| Ulf Erik Jonsson | Board of Directors | 0 companies |
| Klementina Österberg | Deputy Board Member | 0 companies |
| Bo Erik Ulfson Söderpalm | Board of Directors | 0 companies |
| Tomas Per Magnus Bergström | Deputy Board Member | 0 companies |
| James John Gamgort | Board of Directors | 0 companies |
| Marcus Anton Pablo Trummer | Board of Directors | 0 companies |
| Bengt Anders Waas | Chairman | 0 companies |
| Jan Roland Pilebjer | Deputy Board Member | 0 companies |
| Elin Stina Maria Löf | Board of Directors | 0 companies |
| Andrea de Bejczy | Deputy Board Member | 0 companies |
| Frida Louise Åkerblom | Board of Directors | 0 companies |
| Lars Hallmayer | Board of Directors | 0 companies |
| Anders Harald Milton | Board of Directors | 0 companies |
| Jan-Fredrik Wilhelm Backman | Chairman | 0 companies |